[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CerbaXpert\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":149},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,62,88,110,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100563969","accupower--hbv-performance-evaluation-quant-kit-bioneer-existation-fa-96384-100563969",false,"NCT06623071","Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96\u002F384","Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation™FA 96\u002F384","BIOPERF-HBV","Inclusion Criteria:\n\nThe patient to be included in this study must be able to understand the purpose research, in order to give free and informed consent.\n\n* Subject aged over 18\n* Subject presenting himself at the investigation center and responding to one of these two criteria:\n\n  * Subject presenting with a prescription for determination HBV viral load\n  * Subject with previously confirmed HBV infection by CE marked tests.\n* Subject capable of understanding the aim of the research having given express free and informed consent\n* Subject affiliated to or beneficiary of a social security system\n\nExclusion Criteria:\n\nProtected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial decision or administrative\n\n• Subject participating in another clinical study","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","1 Day","OBSERVATIONAL","As part of the CE marking of a hepatitis B diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017\u002F746).\n\nCerba Xpert CRO of the Cerba Healthcare group promoted this performance study by setting up a prospective collection of blood samples from patients with hepatitis B virus and whose viral load is positive. This prospective collection will be carried out in 3 laboratories of the Cerba Healthcare group.",[26],"Hepatitis B",[28],"HBV","RECRUITING","2025-03-24",{"date":32,"type":33},"2025-03-26","ACTUAL",{"date":35,"type":33},"2024-10-01",{"date":37,"type":21},"2025-05-31",{"name":39,"class":40},"CerbaXpert","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100563968","accupower--hcv-performance-evaluation-quant-kit-bioneer-existationfa-96384-100563968","NCT06623058","Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96\u002F384","BIOPERF-HCV","Inclusion Criteria:\n\nThe patient to be included in this study must be able to understand the purpose of the research, in order to to give free and informed consent.\n\n* Subject aged over 18\n* Subject presenting at the investigation center and meeting one of these two criteria:\n\n  * Subject presenting with a prescription for HCV viral load determination\n  * Subject whose HCV infection is previously confirmed by CE marked tests.\n* Subject capable of understanding the purpose of the research having given express free and informed consent\n* Subject affiliated to or beneficiary of a social security system\n\nExclusion Criteria:\n\nProtected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial decision or administrative Subject participating in a clinical study\u002Freceiving investigational treatment\n\n\\-",{"count":20,"type":21},"As part of the CE marking of a hepatitis C diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017\u002F746).\n\nCerba Xpert CRO of the Cerba Healthcare group promoted this performance study by setting up a prospective collection of blood samples from patients suffering from the virus hepatitis C and whose viral load is positive. This prospective collection will be carried out in 4 laboratories of the Cerba Healthcare group.",[52],"HEPATITIS C (HCV)","NOT_YET_RECRUITING","2024-10-02",{"date":56,"type":33},"2024-10-03",{"date":35,"type":21},{"date":59,"type":21},"2025-05-30",{"name":39,"class":40},1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100544793","longitudinal-evaluation-of-antibody-kinetics-of-vaccinated-patients-with-non-mandatory-vaccine-following-administration-of-a-non-public-marketed-vaccine-in-the-general-population-real-life-study-100544793","NCT06373510","Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study","Longitudinal Evaluation of Antibody Kinetics Following Administration of a Non-mandatory Marketed Vaccine in the General Population, Real-life Study","ELCAV","Inclusion Criteria:\n\n* Subject over 18 years of age\n* Subject presenting to the investigation centre as part of its usual management (prevention, screening, tracking)\n* Subject who has been vaccinated and\u002For wishes to be vaccinated\n* Subject able to understand the purpose of research that has given free and informed express consent\n* Member or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Protected subject: major under guardianship, curatorship or other legal protection, deprived of liberty by decision judicial or administrative",true,"90 Years",{"count":73,"type":21},10000,"INTERVENTIONAL",[76],"NA","The study would make it possible to document more explicitly the evolution of antibody titers at following a non-public vaccination over a large post-vaccination period in the French population .\n\nAnalysis of real-life data would enhance knowledge of vaccine response kinetics It would be useful to identify possible early declines requiring doses Similarly, by analyzing antibody kinetics by age, sex, and vaccination status, the would be possible to determine whether there are differences in the immune response between these different sub-groups. In addition, it would provide additional information to assess the real impact of these non-public vaccines in public health and guide vaccine policies.",[79],"Vaccination Reaction","2024-04-15",{"date":82,"type":33},"2024-04-18",{"date":84,"type":21},"2024-06-20",{"date":86,"type":21},"2027-04-03",{"name":39,"class":40},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":74,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100544618","study-of-the-transmission-of-anti-interferon-type-1-alpha-autoantibodies-from-mother-to-child-via-the-placental-barrier-100544618","NCT06371235","Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier","Pregiferon","Inclusion Criteria:\n\n* Pregnant woman over 18 years old\n* Woman whose gestational age is less than 30 weeks.\n* Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks\n* Give birth in the inclusion center\n* Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status\n* Affiliated with the Social Security system\n\nExclusion Criteria:\n\n* Patient who underwent a blood transfusion less than 2 months ago\n* Patient who received an organ transplant\n* Patient undergoing immunotherapy, stem cell therapy and\u002For other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion","FEMALE",{"count":97,"type":21},250,[76],"The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy.",[101],"Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons","2024-04-12",{"date":104,"type":33},"2024-04-17",{"date":106,"type":21},"2024-09",{"date":108,"type":21},"2027-03",{"name":39,"class":40},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":74,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100527174","collection-of-additional-biological-samples-from-potentially-covid-19-patients-for-monitoring-of-biological-parameters-carried-out-as-part-of-the-routine-100527174","NCT06144333","Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine","CEB Covid-19","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient coming for a biological analysis as part of the care for prevention, screening or monitoring of the pathogen target\n* Patient able to understand the information note and give a free and informed consent, on paper or digital media\n* Clinical patients:\n\n  * Control cases (all comers or ambulatory)\n  * Known positive for the pathology concerned\n  * Patient hospitalized for the pathology concerned\n* Pregnant or breastfeeding patient\n* Dialysis patient\n\nExclusion Criteria:\n\n* Patient already included in a research protocol\n* Patient having received medication or treatment experimental or investigational during the last four weeks before collection\n* Patient subject to a legal protection measure\n* Patient affiliated with state medical aid (AME)\n* Patient not affiliated to the compulsory Social Security system\n* Refusal or inability to provide signed informed consent\n* According to the investigator, the patient is not eligible for inclusion in the study",{"count":118,"type":21},7500,[76],"Patients infected with SARS-CoV-2 can present with a wide range of manifestations clinical conditions, ranging from no symptoms to serious or chronic illness. The current gold standard test for the diagnosis of COVID-19 is based on a molecular test of reverse transcription polymerase chain reaction (RT-PCR), aimed at detecting the RNA of the virus in respiratory samples such as nasopharyngeal swabs or aspirates bronchial, other methods such as antigen tests and serological detection tests IgM and IgG in response to COVID-19 viral infection, can be used for the purposes of screening in the general population.\n\nIn this context of variety of existing tests, it is important to monitor the biological parameters related to COVID-19 pathology by tracking the accuracy, specificity and sensitivity of these tests in current clinical practice.\n\nThis research is a collection of additional biological samples with minimal impact on the intake usual care of the patients concerned, for the monitoring of biological parameters carried out in routine on several reagent kits used for screening for the SARS-CoV-2 virus, in terms of sensitivity, specificity, positive and negative predictive values, for the implementation of indicators quality monitoring of these kits.",[122],"SARS CoV 2 Infection",{"date":80,"type":33},{"date":125,"type":21},"2024-12-23",{"date":127,"type":21},"2026-11-23",{"name":39,"class":40},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":23,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100514836","prevalence-of-sexually-transmitted-infections-stis-and-coinfections-in-the-general-population-100514836","NCT05983679","Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General Population","Prevalence of Sexually Transmitted Infections (STIs) and Co-infections in the General Population","PREMINF","Inclusion Criteria:\n\n* Subject, male or female, 18 years of age or older\n* Subject capable of understanding the purpose of the research having given their free and informed written consent\n* Subject presenting to the laboratory for a biological examination\n* Affiliated subject or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n\\- Protected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision",{"count":138,"type":21},9000,"3 Years","Prevalence of Sexually Transmitted Infections (STIs) and co-infections in the general population",[142],"HIV Infections",{"date":80,"type":33},{"date":145,"type":21},"2024-12-04",{"date":147,"type":21},"2026-09-04",{"name":39,"class":40},""]